How Will Memphasys AU$800,000 Capital Raise Support Felix™ System Expansion?
Source: Kapitales Research
Highlights:
Memphasys Limited (ASX: MEM) has raised AU$800,000 through a share placement at AU$0.005 per share.
The placement received significant backing from both new and existing institutional investors, alongside sophisticated and professional investors.
The funds will be used to support the Felix™ System’s commercial execution, including the scaling of direct selling, meeting manufacturing demands, and advancing regulatory approvals in key markets.
Capital Raise to Accelerate Commercial Growth
Memphasys Limited (ASX: MEM) has successfully raised AU$800,000 through a share placement, issuing 160 million new shares at AU$0.005 per share. The placement was well-received by a mix of new and existing investors, reflecting strong confidence in the company’s growing momentum.
The funds will be applied toward advancing the Felix™ System’s commercialization, particularly focusing on increasing direct selling efforts, scaling manufacturing to meet growing demand, and progressing regulatory approvals in important international markets. These initiatives will help position Felix™ as a key player in the field of reproductive biotechnology, with a focus on human-assisted reproduction.
Strategic Use of Funds
Proceeds from the capital raise will be directed to a number of strategic initiatives. At the time of writing, the company plans to expand its direct sales model, enhance clinical engagement activities, and support the scaling of manufacturing processes to meet both contracted and anticipated customer demand. Additionally, the funds will be used to progress regulatory approvals in critical markets like Australia and India, which is essential for the ongoing commercial expansion of the Felix™ System.
Placement Details and Investor Support
The placement saw the issuance of 160 million fully paid ordinary shares under Memphasys’s ASX Listing Rule 7.1 placement capacity. At the time of writing, the AU$0.005 issue price represented a 28.6% discount to the last closing price of AU$0.007, and a 22.5% discount to the 10-day volume weighted average price (VWAP).
The company has set the settlement date for 13 February 2026, with the shares expected to be allocated on or around 16 February 2026.
Leadership Commentary
Dr. Lindley Edwards, Chair of Memphasys, expressed satisfaction with the strong investor backing, emphasizing that the capital raise will help the company build on its recent achievements. With CE Mark approval for the Felix™ System secured, initial revenues now being invoiced, and contracted demand already in place, this funding will allow Memphasys to accelerate its commercial efforts and move towards recurring revenue growth.
Outlook
With the successful raise of AU$800,000, Memphasys is positioned to strengthen its commercial capabilities, scale its production efforts, and advance regulatory approvals. Investors will likely be focused on the company’s ability to implement its commercial strategies effectively, grow its market share in assisted reproductive technology (ART), and meet increasing customer demand in the coming months.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
How Will Memphasys AU$800,000 Capital Raise Support Felix™ System Expansion?
Highlights:
Capital Raise to Accelerate Commercial Growth
Memphasys Limited (ASX: MEM) has successfully raised AU$800,000 through a share placement, issuing 160 million new shares at AU$0.005 per share. The placement was well-received by a mix of new and existing investors, reflecting strong confidence in the company’s growing momentum.
The funds will be applied toward advancing the Felix™ System’s commercialization, particularly focusing on increasing direct selling efforts, scaling manufacturing to meet growing demand, and progressing regulatory approvals in important international markets. These initiatives will help position Felix™ as a key player in the field of reproductive biotechnology, with a focus on human-assisted reproduction.
Strategic Use of Funds
Proceeds from the capital raise will be directed to a number of strategic initiatives. At the time of writing, the company plans to expand its direct sales model, enhance clinical engagement activities, and support the scaling of manufacturing processes to meet both contracted and anticipated customer demand. Additionally, the funds will be used to progress regulatory approvals in critical markets like Australia and India, which is essential for the ongoing commercial expansion of the Felix™ System.
Placement Details and Investor Support
The placement saw the issuance of 160 million fully paid ordinary shares under Memphasys’s ASX Listing Rule 7.1 placement capacity. At the time of writing, the AU$0.005 issue price represented a 28.6% discount to the last closing price of AU$0.007, and a 22.5% discount to the 10-day volume weighted average price (VWAP).
The company has set the settlement date for 13 February 2026, with the shares expected to be allocated on or around 16 February 2026.
Leadership Commentary
Dr. Lindley Edwards, Chair of Memphasys, expressed satisfaction with the strong investor backing, emphasizing that the capital raise will help the company build on its recent achievements. With CE Mark approval for the Felix™ System secured, initial revenues now being invoiced, and contracted demand already in place, this funding will allow Memphasys to accelerate its commercial efforts and move towards recurring revenue growth.
Outlook
With the successful raise of AU$800,000, Memphasys is positioned to strengthen its commercial capabilities, scale its production efforts, and advance regulatory approvals. Investors will likely be focused on the company’s ability to implement its commercial strategies effectively, grow its market share in assisted reproductive technology (ART), and meet increasing customer demand in the coming months.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au